Agilent Technologies, Inc. $A Shares Purchased by Creative Planning

Creative Planning increased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 112.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,846 shares of the medical research company’s stock after purchasing an additional 48,533 shares during the quarter. Creative Planning’s holdings in Agilent Technologies were worth $10,839,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Agilent Technologies by 7.2% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 69,923 shares of the medical research company’s stock worth $8,252,000 after buying an additional 4,681 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Agilent Technologies by 10.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company’s stock valued at $1,560,964,000 after acquiring an additional 1,273,994 shares in the last quarter. Clearstead Trust LLC grew its stake in Agilent Technologies by 228.7% during the 2nd quarter. Clearstead Trust LLC now owns 894 shares of the medical research company’s stock valued at $106,000 after acquiring an additional 622 shares in the last quarter. ABN Amro Investment Solutions acquired a new stake in Agilent Technologies in the 2nd quarter valued at about $2,820,000. Finally, Candriam S.C.A. lifted its stake in Agilent Technologies by 2.4% in the 2nd quarter. Candriam S.C.A. now owns 533,466 shares of the medical research company’s stock worth $62,957,000 after purchasing an additional 12,510 shares in the last quarter. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Agilent Technologies Trading Down 0.5%

A opened at $143.86 on Wednesday. The stock has a market capitalization of $40.78 billion, a PE ratio of 33.77, a P/E/G ratio of 4.67 and a beta of 1.29. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The business’s 50 day moving average price is $138.31 and its 200 day moving average price is $124.52.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts’ consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the previous year, the business earned $1.32 earnings per share. The company’s revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th were paid a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Tuesday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is 23.24%.

Analyst Upgrades and Downgrades

A has been the subject of a number of analyst reports. TD Cowen upped their price target on Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Evercore ISI upped their target price on Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. Barclays raised their target price on Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Rothschild & Co Redburn started coverage on shares of Agilent Technologies in a research report on Wednesday, October 8th. They set a “buy” rating and a $165.00 price target on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Agilent Technologies in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $149.62.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 12,490 shares of Agilent Technologies stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the completion of the sale, the chief executive officer directly owned 33,448 shares in the company, valued at $5,017,200. This trade represents a 27.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by company insiders.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.